Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial)

Tools
- Tools
+ Tools

Patel, Jaimin M., Snaith, Catherine, Thickett, David R., Linhartova, Lucie, Melody, Teresa, Hawkey, P. M., Barnett, A. H., Jones, Alan, Hong, Tan, Cooke, Matthew, Perkins, Gavin D. and Smith, F. Gao (2012) Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial). Critical Care, Volume 16 (Number 6). Article number R231. doi:10.1186/cc11895 ISSN 1466-609X.

[img]
Preview
Text
WRAP_Perkins_cc11895.pdf - Published Version
Available under License Creative Commons Attribution 2.0..

Download (460Kb) | Preview
Official URL: http://dx.doi.org/10.1186/cc11895

Request Changes to record.

Abstract

Introduction: Several observational studies suggest that statins modulate the pathophysiology of sepsis and may
prevent its progression. The aim of this study was to determine if the acute administration of atorvastatin reduces
sepsis progression in statin naïve patients hospitalized with sepsis.

Methods: A single centre phase II randomized double-blind placebo-controlled trial. Patients with sepsis were
randomized to atorvastatin 40 mg daily or placebo for the duration of their hospital stay up to a maximum of
28-days. The primary end-point was the rate of sepsis progressing to severe sepsis during hospitalization.

Results: 100 patients were randomized, 49 to the treatment with atorvastatin and 51 to placebo. Patients in the
atorvastatin group had a significantly lower conversion rate to severe sepsis compared to placebo (4% vs. 24% p =
0.007.), with a number needed to treat of 5. No significant difference in length of hospital stay, critical care unit
admissions, 28-day and 12-month readmissions or mortality was observed. Plasma cholesterol and albumin
creatinine ratios were significantly lower at day 4 in the atorvastatin group (p < 0.0001 and p = 0.049 respectively).
No difference in adverse events between the two groups was observed (p = 0.238).

Conclusions: Acute administration of atorvastatin in patients with sepsis may prevent sepsis progression. Further
multi-centre trials are required to verify these findings.

Trial Registration: International Standard Randomized Control Trial Registry ISRCTN64637517.

Item Type: Journal Article
Subjects: R Medicine > R Medicine (General)
R Medicine > RM Therapeutics. Pharmacology
Divisions: Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Septicemia, Blood -- Diseases , Clinical trials, Clinical medicine -- Research, Statins (Cardiovascular agents), Hospital patients
Journal or Publication Title: Critical Care
Publisher: BioMed Central Ltd.
ISSN: 1466-609X
Official Date: 11 December 2012
Dates:
DateEvent
11 December 2012Published
Volume: Volume 16
Number: Number 6
Page Range: Article number R231
DOI: 10.1186/cc11895
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access (Creative Commons)
Date of first compliant deposit: 24 December 2015
Date of first compliant Open Access: 24 December 2015
Funder: J P Moulton Charitable Foundation, Pfizer Inc.

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us